Abstract: Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, for example, treat or prevent infectious disease. In addition, after activating the innate immune system, immunogenic compositions further containing an antigen may be used to elicit a specific adaptive immune response. Furthermore, provided are compositions capable of altering hyperreactive responses or inflammatory immune responses, such as allergic reactions. Such compositions may be used as a prophylactic, or in various clinical settings to treat or prevent infectious disease (such as parasite, fungal, bacterial or viral infections), or to alter inappropriate inflammatory immune responses (such as allergic reactions or asthma).
Type:
Grant
Filed:
April 28, 2014
Date of Patent:
September 6, 2016
Assignee:
ID Biomedical Corporation of Quebec
Inventors:
George H. Lowell, David S. Burt, David Hugh Jones, Joseph J. Zimmermann, Clement Rioux
Abstract: Described are human binding molecules specifically binding to enterococci and having killing activity against enterococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the molecules. The molecules can be used, for example, in the diagnosis, prophylaxis, and/or treatment of a condition resulting from Enterococcus.
Type:
Grant
Filed:
December 10, 2013
Date of Patent:
August 30, 2016
Assignee:
Janssen Vaccines & Prevention B.V.
Inventors:
Mark Throsby, Robert A. Kramer, Cornelis A. de Kruif
Abstract: The invention provides a general and facile method to obtain secondary metabolites from fungal sources. The invention is based on the discovery that the fungal gene veA and protein encoded thereby regulates the activity of multiple secondary metabolite gene clusters in fungi. Over expression of the gene veA provides increased production of secondary metabolites in engineered cells. In particular, such a method of increasing secondary metabolite production allows the production of improved yields of valuable secondary metabolite products.
Abstract: The invention concerns a peptide or arrangement of peptides forming a Staphylococcus aureus epitope binding site comprising a first amino acid sequence and a second amino acid sequence, wherein the first amino acid sequence is at least 88% identical to sequence SEQ ID NO:1 and wherein the second amino acid sequence is at least 88% identical to sequence SEQ ID NO: 2.
Type:
Grant
Filed:
September 21, 2012
Date of Patent:
August 23, 2016
Assignee:
JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG
Inventors:
Knut Ohlsen, Udo Lorenz, Roland E. Kontermann
Abstract: There is provided a NetB epitope polypeptide comprising at least 10 contiguous amino acids from SEQ ID NO:1 and comprising a mutation in at least one position between amino acids 130 and 297 as compared with the equivalent position in SEQ ID NO:3, the mutation preferably being located within a rim domain, the polypeptide being capable of binding an antibody which binds to SEQ ID NO:1 and having reduced toxicity compared with the toxicity of SEQ ID NO:1. The polypeptide is useful to vaccinate a subject against infection by Clostridium perfringens.
Type:
Grant
Filed:
October 24, 2012
Date of Patent:
August 23, 2016
Assignee:
University of Exeter
Inventors:
Richard W. Titball, Sérgio Paulo Fernandes Da Costa, Claire Naylor, Ajit Basak
Abstract: Vaccines are disclosed against parasites. The vaccines include peptides in an immunological composition. In particular, the parasite is Toxoplas gondii.
Type:
Grant
Filed:
November 3, 2011
Date of Patent:
August 9, 2016
Assignees:
The University of Chicago, Infectious Disease Research Institute, Paxvax, Inc.
Inventors:
Rima McLeod, Tze Guan Tan, Jeffery L. Alexander, Hua Cong, William H. Witola, Kamal El Bissati, Ernest J. Mui, Steven G. Reed
Abstract: Methods and reagents for ameliorating biofilm formation on a surface of an indwelling or implanted device in a patient resulting in decreased virulence of microorganisms such as Candida species and/or Staphylococcus species.
Type:
Grant
Filed:
October 20, 2014
Date of Patent:
August 9, 2016
Assignees:
Children's Hospital Medical Center, University of Cincinnati, Yale University
Inventors:
Margaret K. Hostetter, Long Lu, Julianne Vernadette Green, Alexey Porollo, Kris I. Orsborn, Khoon Ghee Queenie Tan, Kenneth Greis, David Andes
Abstract: The present invention relates to compositions comprising Haemophilus influenzae Protein E and Pilin A. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising Protein E and PilA, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
Type:
Grant
Filed:
December 16, 2014
Date of Patent:
August 9, 2016
Assignee:
GLAXOSMITHKLINE BIOLOGICALS S.A.
Inventors:
Normand Blais, Steve Labbe, Jan Poolman
Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides , Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
Abstract: The disclosure relates to an anti-Pseudomonas PSL binding molecule and uses thereof, in particular, in prevention and treatment of Pseudomonas infection. Furthermore, the disclosure provides compositions and methods for preventing and treating Pseudomonas infection.
Type:
Grant
Filed:
June 8, 2012
Date of Patent:
August 2, 2016
Assignees:
MedImmune, LLC, MedImmune Limited
Inventors:
Antonio Digiandomenico, Paul G. Warrener, Charles K. Stover, Brett Sellman, Sandrine Guillard, Ralph Minter, Steven Rust, Mladen Tomich
Abstract: Streptococcus pneumoniae is a major health concern, especially in very young, elderly, or immunocompromized patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in Streptococcus pneumoniae. The antigens may be used therapeutically or prophylactically.
Type:
Grant
Filed:
January 20, 2012
Date of Patent:
July 19, 2016
Assignees:
Genocea Biosciences, Inc., Children's Medical Center Corporation
Abstract: The invention relates to bacterial lipopolysaccharide and its components, especially native and chemically modified polysaccharides isolated from Hafnia alvei lipopolysaccharides, as well as conjugates of these polysaccharides with carriers and methods for their preparation and methods to use of these substances as ligands for human ficolin-3.
Type:
Grant
Filed:
June 11, 2011
Date of Patent:
July 5, 2016
Assignees:
INSTYTUT BIOLOGII MEDYCZNEJ POLSKIEJ AKADEMII NAUK, INSTYTUT IMMUNOLOGII I TERAPII DOSWIADCZALNEJ PAN
Inventors:
Jolanta Lukasiewicz, Anna Swierzko, Maciej Cedzynski, Czeslaw Lugowski, Anna Maciejewska, Wojciech Jachymek, Tomasz Niedziela
Abstract: The present invention relates to non-replicating probiotic micro-organisms and their health benefits. For example, the present invention relates to compositions comprising non-replicating probiotic micro-organisms for use in the treatment of prevention of upper respiratory tract infections and/or their symptoms. Embodiments of the present invention provide means to help parents to protect their children from such upper respiratory tract infections.
Type:
Grant
Filed:
November 9, 2011
Date of Patent:
June 21, 2016
Assignee:
Nestec S.A.
Inventors:
Valerie Petit, Clara Lucia Garcia-Rodenas, Monique Julita, Annick Mercenier, Guenolee Prioult, Sophie Nutten
Abstract: The invention relates to a novel use of a Bordetella adenylcyclase toxin in the manufacturing of vectors for targeting in vivo a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses, to pharmaceutical compositions and to a new vector for molecule delivery to CD11b expressing cells.
Type:
Grant
Filed:
June 27, 2011
Date of Patent:
June 21, 2016
Assignees:
INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Inventors:
Claude LeClerc, Pierre Guermonprez, Daniel Ladant, Nicole Guiso, Nadia Khelef, Cecile Bauche, Catherine Fayolle, Mohammed El-Azami El-Idrissi
Abstract: This invention relates to use of probiotics, particularly P acidilactici and S boulardii, for use in conjunction with steroids and other immune suppressor agents to ameliorate symptoms of autoimmune diseases, especially disease symptoms arising from the body's production of antibodies against autologous blood cells. The practice of the invention sustains ameliorative response associated with immune suppressor agents while lowering the amount of immune suppressor agents required for treatment.
Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.
Type:
Grant
Filed:
January 25, 2009
Date of Patent:
June 7, 2016
Assignees:
GAVISH-GALILEE BIO APPLICATIONS LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
Inventors:
Jacob Pitcovski, Ehud Shahar, Raphael Gorodetsky
Abstract: Described herein are methods for purifying recombinant, cell culture derived alpha1-protease inhibitor and removing a colored species that co-purifies with the recA1PI protein. Also described are methods for reducing the iron in cell culture derived alpha1-protease inhibitor.
Type:
Grant
Filed:
March 14, 2013
Date of Patent:
May 31, 2016
Assignee:
Grifols, S.A.
Inventors:
David Ownby, Thomas P. Zimmerman, Jennifer A. Hunt, Charles Miller, Senthil Ranganathan, Tonny Dessources
Abstract: The present invention relates to non-replicating probiotic micro-organisms and their health benefits. In particular, the present invention provides a means to help parents to protect their children from gastro-intestinal infections, in particular diarrhea. One embodiment of the present invention relates to a composition comprising non-replicating probiotic micro-organisms for use in the prevention or treatment of gastrointestinal infections in children.
Type:
Grant
Filed:
November 9, 2011
Date of Patent:
May 24, 2016
Assignee:
Nestec S.A.
Inventors:
Valerie Petit, Clara Lucia Garcia-Rodenas, Monique Julita, Annick Mercenier, Guenolee Prioult, Sophie Nutten
Abstract: Compositions and methods are provided, comprising at least one beta-lactam compound selected from the group consisting of cefuroxime, a penicillin, ceftriaxone, clavulanic acid, 6-aminopenicillanic acid (6-APA) and tazobactam, for enhancing T cell mediated immune responses in a subject, such as anti-tumor and anti-viral immune responses.